RE-BVS – Piemonte Repository

Sfoglia per AUTORE
RIVOLI G
Collezione ASL Torino 4

Items : 2

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
AOU Alessandria
ASL Città di Torino
ASL Torino 4
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Della Porta MG; Santini V; Naldi I; Finelli C; Sancetta R; Selleri C; Pasini P; Giordano L; Turrini M; Tosi P; Tanasi I; Frigeni M; Grimaldi D; Marchetti M; Norata M; Galimberti S; Fianchi L; Di Veroli A; Ferrara F; Di Bona E; Bono R; Castelli A; Calvisi A; Rivoli G; Molteni A; Nicolino B; Occhini U; Leuzzi L; Genua A; et alii...

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Torino 4
ASL Biella

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...